Spiriva
$ 90,00 – $ 470,00Price range: $ 90,00 through $ 470,00
Strattera
$ 40,00 – $ 500,00Price range: $ 40,00 through $ 500,00
Starlix
$ 40,00 – $ 288,00Price range: $ 40,00 through $ 288,00
Starlix is an oral medication specifically designed to help manage blood sugar levels in adults with type 2 diabetes. This medication works by stimulating the pancreas to produce more insulin shortly after a meal, effectively controlling post-meal glucose spikes. It is typically used in conjunction with a healthy diet and regular physical activity to improve overall glycemic control. Starlix can be taken alone or in combination with other anti-diabetic medications like metformin to help achieve target A1C levels. By maintaining stable blood sugar throughout the day, this treatment helps reduce the long-term health risks associated with high glucose levels.
Active substance: Nateglinide
SKU:
Starlix
Categories: AntiVirals, Gastrointestinal Tract
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Starlix belongs to a class of oral antidiabetic medications known as meglitinides, or D-phenylalanine derivatives. The drug contains the active ingredient nateglinide, which stimulates pancreatic beta cells to release insulin in direct response to food intake. This prescription medication is indicated for adult patients with type 2 diabetes mellitus to assist in achieving adequate glycemic control.
Administered orally shortly prior to meals, Starlix specifically targets postprandial blood glucose elevations to optimize daily glycemic management. Safe and effective clinical utility requires integration with individualized nutritional management, structured exercise, and routine clinical monitoring under the direction of a licensed healthcare provider.
| Parameter | Specification |
|---|---|
| Active ingredient | Nateglinide |
| Therapeutic class | Meglitinide antidiabetic agent |
| Dosage form | Oral tablet |
| Route of administration | Oral |
| Primary purpose | Glycemic control in type 2 diabetes mellitus |
| Prescription status | Prescription only (Rx) |
Pharmacology and Clinical Profile
Main Uses and Mechanism
Main uses
Starlix is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be prescribed as monotherapy or in combination with other oral antidiabetic agents, such as metformin or thiazolidinediones, when single-agent therapy does not provide adequate blood sugar regulation. The therapeutic objective of Starlix is to reduce both fasting blood glucose levels and postprandial glucose spikes. Starlix is not indicated for the treatment of type 1 diabetes mellitus or for the management of diabetic ketoacidosis, as these conditions involve an absolute deficiency of endogenous insulin secretion that cannot be resolved by beta-cell stimulation.
How the drug works
The mechanism of action of Starlix involves the rapid stimulation of insulin secretion from functioning pancreatic beta cells. Nateglinide binds to specific ATP-dependent potassium (K+ATP) channels on the beta-cell membrane, causing channel closure. This event induces membrane depolarization, which subsequently opens voltage-gated calcium channels. The influx of extracellular calcium triggers the exocytosis of pre-stored insulin granules into the bloodstream. Unlike sulfonylureas, nateglinide interacts with the pancreatic beta cell via a distinct binding site with rapid association and dissociation kinetics. This characteristic yields a swift, short-duration insulinotropic response specifically timed to meal ingestion, thereby reducing the duration of hyperinsulinemia between meals.
Pharmacokinetics and Dosage Schedule
What happens in the body
Following oral administration, nateglinide is rapidly and almost completely absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1 hour. The absolute oral bioavailability of Starlix is approximately 73%. Systemic exposure is proportional to the dose over the clinical range of 60 mg to 240 mg. Nateglinide is highly bound to plasma proteins (approximately 98%), primarily serum albumin. The drug undergoes extensive hepatic metabolism, predominantly mediated by the cytochrome P450 isoenzyme CYP2C9 (approximately 70%) and to a lesser extent by CYP3A4 (approximately 30%). The primary metabolites possess significantly less pharmacological activity than the parent compound. Elimination occurs rapidly, with an elimination half-life of approximately 1.5 hours. Approximately 83% of a radiolabeled dose is excreted in the urine, while 10% is eliminated in the feces.
Dosing schedule
The recommended starting and maintenance dose of Starlix for most patients is 120 mg taken orally three times daily, administered 1 to 30 minutes prior to major meals. For patients who are near their target HbA1c goal upon initiation of therapy, a starting dose of 60 mg three times daily may be considered. Tablets should be swallowed whole with water. Because Starlix acts primarily by stimulating mealtime insulin secretion, the medication should be taken only prior to meals. If a meal is skipped or delayed, the corresponding dose of Starlix must also be omitted to prevent the occurrence of severe hypoglycemia. Dosing adjustments are guided by regular blood glucose measurements and HbA1c evaluations under clinical supervision.
Safety, Precautions, and Patient Care
Precautions, Interactions, and Side Effects
What to avoid while taking it
Concomitant consumption of alcohol during Starlix therapy can alter blood glucose control and significantly potentiate the risk of severe hypoglycemia. Patients should refrain from excessive alcohol intake. In addition, dietary inconsistency poses a major safety risk: skipping meals after taking a dose of nateglinide dramatically increases the probability of low blood sugar events. Patients should also avoid combining Starlix with other meglitinides or secretagogues unless explicitly instructed by a physician.
Compatibility with other medicines
The hypoglycemic action of Starlix may be enhanced when co-administered with nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors (MAOIs), non-selective beta-adrenergic blocking agents, and CYP2C9 inhibitors such as fluconazole. Conversely, the blood glucose-lowering effect may be diminished by co-administration with thiazide diuretics, corticosteroids, thyroid products, sympathomimetics, and CYP2C9/CYP3A4 inducers such as rifampin. Beta-blockers may also mask early warning signs of hypoglycemia, such as tachycardia and tremors, requiring heightened clinical vigilance.
Important precautions
Hypoglycemia is the primary clinical risk associated with Starlix therapy. Elderly patients, malnourished individuals, and those with adrenal or pituitary insufficiency are particularly susceptible to severe low blood sugar events. Caution is warranted in patients with moderate-to-severe hepatic impairment, as nateglinide undergoes extensive liver metabolism, potentially leading to increased systemic drug exposure. In cases of severe renal impairment, although renal excretion of unchanged drug is minor, accumulated metabolites require careful clinical monitoring.
Adverse reactions
Clinical trials have identified hypoglycemia as the most common adverse reaction associated with Starlix. Other frequently reported adverse events include upper respiratory tract infection, back pain, flu-like symptoms, dizziness, arthropathy, and accidental injury. Gastrointestinal side effects, such as diarrhea and dyspepsia, may also occur. Hypersensitivity reactions, including rash, pruritus, and urticaria, have been reported in rare cases. Patients experiencing signs of severe hypersensitivity or prolonged low blood sugar should obtain prompt medical evaluation.
| Adverse Clinical Manifestation | Recommended Action |
|---|---|
| Swelling of the face, lips, tongue, or throat | Seek immediate emergency medical attention |
| Severe hypoglycemia (confusion, seizures, loss of consciousness) | Administer emergency glucose/glucagon and seek immediate help |
| Severe cutaneous reactions (blistering, peeling rash) | Discontinue use and obtain immediate medical assessment |
| Signs of hepatic dysfunction (jaundice, dark urine, severe abdominal pain) | Contact a healthcare provider immediately |
If you skip a dose
If a dose of Starlix is forgotten prior to a meal, the dose should be skipped entirely if the meal has already been completed. The patient should resume the standard dosing schedule with the next scheduled meal. Under no circumstances should a double dose be administered to compensate for a missed tablet, as this significantly heightens the risk of acute hypoglycemia.
Special populations
Starlix is classified as Pregnancy Category C. Adequate and well-controlled studies in pregnant women are lacking; therefore, nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether nateglinide is excreted in human milk; a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Safety and effectiveness in pediatric patients have not been established. Clinical trials showed no overall differences in safety or effectiveness between elderly patients and younger adults, though increased sensitivity in some older individuals cannot be ruled out.
Day-to-day use
Patients prescribed Starlix should maintain a consistent daily meal routine and carry a fast-acting source of oral glucose, such as glucose tablets or gel, at all times to manage unexpected hypoglycemic episodes. Routine self-monitoring of blood glucose levels is essential for assessing treatment efficacy and adjusting dosage regimens. Patients undergoing stress, fever, trauma, or surgery may experience temporary disruption of glycemic control, requiring temporary adjustments to their antidiabetic treatment plan under medical advice.
Common Questions
What is the mechanism by which Starlix controls postprandial glucose levels?
Starlix contains nateglinide, an amino acid derivative that stimulates rapid, transient insulin release from pancreatic beta cells upon meal consumption. By selectively targeting early-phase insulin secretion, it minimizes post-meal blood sugar spikes without causing prolonged hyperinsulinemia between meals.
Should Starlix be taken if a meal is skipped?
No. Because Starlix is engineered to stimulate insulin secretion specifically in response to ingested carbohydrates, skipping a meal requires skipping the corresponding dose. Taking the drug without food intake creates a high risk of drug-induced hypoglycemia.
Can Starlix be combined with other antidiabetic agents?
Yes, Starlix may be prescribed in combination with other oral antidiabetic agents, such as metformin or thiazolidinediones, to achieve enhanced glycemic control. However, it should not be combined with other meglitinides or sulfonylureas due to overlapping mechanisms of action and increased hypoglycemia risk.
How rapidly does Starlix take effect after administration?
Peak plasma concentrations of nateglinide are reached within 1 hour following oral administration. Its rapid onset necessitates taking the medication immediately before or up to 30 minutes prior to a meal.
What laboratory parameters are utilized to monitor Starlix treatment response?
Treatment response is routinely evaluated using glycosylated hemoglobin (HbA1c) measurements and self-monitored blood glucose levels. Glycated hemoglobin reflects long-term glycemic control, while pre-meal and postprandial blood glucose tests assess acute drug efficacy.
In accordance with FDA requirements.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
120mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills ,120 pills ,180 pills ,270 pills ,360 pills |
| Ενεργός Ουσία |
Related products
Ascorbic Acid
$ 58,00 – $ 69,00Price range: $ 58,00 through $ 69,00
Active substance: Ascorbic Acid
More Details
This product has multiple variants. The options may be chosen on the product page
Atacand
$ 42,00 – $ 383,00Price range: $ 42,00 through $ 383,00
Active substance: Candesartan
More Details
This product has multiple variants. The options may be chosen on the product page
Copegus
$ 171,00 – $ 452,00Price range: $ 171,00 through $ 452,00
Active substance: ribavirin
More Details
This product has multiple variants. The options may be chosen on the product page
Famvir
$ 136,00 – $ 285,00Price range: $ 136,00 through $ 285,00
Active substance: Famciclovir
More Details
This product has multiple variants. The options may be chosen on the product page
Sustiva
$ 47,00 – $ 2 412,00Price range: $ 47,00 through $ 2 412,00
Active substance: Efavirenz
More Details
This product has multiple variants. The options may be chosen on the product page
Tamiflu
$ 66,00 – $ 427,00Price range: $ 66,00 through $ 427,00
Active substance: Oseltamivir
More Details
This product has multiple variants. The options may be chosen on the product page
Zovirax
$ 52,00 – $ 587,00Price range: $ 52,00 through $ 587,00
Active substance: Acyclovir
More Details
This product has multiple variants. The options may be chosen on the product page
Zovirax Cream
$ 46,00 – $ 138,00Price range: $ 46,00 through $ 138,00
Active substance: Acyclovir
More Details
This product has multiple variants. The options may be chosen on the product page
